AzTrials
AzTrials

Neuroblastoma RecurrentPhase 2NCT07085338

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

A Phase 2 study testing Temozolomide, Irinotecan and hu14.18K322A in people with Neuroblastoma Recurrent, run by St. Jude Children's Research Hospital at 5 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The study participant is being asked to take part in this research study because the participant has been diagnosed with neuroblastoma that did not fully respond to previous treatment (refractory), or it has returned after treatment (relapsed). Read more about this study

Who is it for?
Ages Up to 30 years
Conditions the study is for
Neuroblastoma Recurrent
What is being tested?
Temozolomide, Irinotecan and hu14.18K322A
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
54 participants
Where
5 sitesUnited States
Study dates
10 Nov 2025to 1 Feb 2029
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 30 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Age
  • Patients must be < 30 at the time of enrollment on study.
  • Diagnosis
  • Patients must have had histologic verification of neuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary or serum catecholamines [i.e., > 2 x upper limit of normal (ULN)], at the time of initial diagnosis.
  • Disease Risk Group
  • Patients must have high-risk neuroblastoma according to COG risk classification at the time of study registration. Patients whose disease was initially considered low or intermediate risk but were then reclassified as high-risk neuroblastoma prior to enrollment are also eligible.
Show all 78Show fewer
  • Response to Prior Therapy (using INRC definitions)
  • Patients must have at least ONE (recurrent/progressive, refractory, or persistent) of the following:
  • Recurrent/progressive disease after the diagnosis of high-risk neuroblastoma at any time prior to enrollment regardless of response to frontline therapy. (Note that this excludes patients initially considered low or intermediate risk that progressed to high-risk disease but have not progressed after the diagnosis of high-risk neuroblastoma).
  • Refractory disease: A best overall response of no response/stable disease since diagnosis of high-risk neuroblastoma AND after at least 4 cycles of induction therapy.
  • Persistent disease: A best overall response of partial response since diagnosis of high-risk neuroblastoma AND after at least 4 cycles of induction therapy
  • Sites of Disease
  • Patients must have at least ONE of the following (lesions may have received prior radiation therapy if they meet the other criteria listed below) based on institutional assessment:
  • Bone Sites
  • MIBG avid tumors: patients must meet one of the following criteria:
  • Patients with recurrent/progressive or refractory disease: i. Must have at least one MIBG avid bone site on planar imaging OR ii. Must have > 2 lesions on SPECT/CT. A biopsy is not required unless the above imaging criteria are not met
  • Patients with persistent disease: i. If a patient has 3 or more MIBG avid bone lesions, then no biopsy is required.
  • If a patient has only 1 or 2 MIBG avid bone lesion sites, then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one MIBG avid site present at the time of enrollment is required. Bone lesions may be biopsied at any time point prior to enrollment.
  • For MIBG non-avid tumors, patients must have at least an FDG-PET avid site and meet the following criteria:
  • Biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment of at least one FDG-PET avid site.
  • Bone Marrow
  • Any amount of tumor cells in the bone marrow (including neuroblasts, mature and maturing ganglion cells) done at the time of study enrollment based on routine morphology and/or immunohistochemistry in at least one sample from bilateral aspirates and biopsies. NOTE: Patients with bone marrow disease only will be eligible if they have more than 5% disease involvement (documented neuroblastoma cells) in at least one sample from bilateral bone marrow biopsies.
  • Soft Tissue Sites
  • At least one soft tissue lesion that meets criteria for a TARGET lesion as defined by:
  • SIZE: Lesion can be accurately measured in at least one dimension with a longest diameter ≥ 10 mm, or for discrete lymph nodes ≥ 15mm on short axis. Lesions meeting size criteria will be considered measurable.
  • In addition to size, a lesion needs to meet ONE of the following criteria except for patients with parenchymal CNS lesions which will only need to meet size criteria:
  • For MIBG avid tumors: lesion must be MIBG avid and meet one of the following criteria: i. For patients with recurrent/progressive or refractory disease: no biopsy is required ii. For patients with persistent disease:
  • If a patient has 3 or more MIBG avid soft tissue lesions, then no biopsy is required.
  • If a patient has only 1 or 2 MIBG avid soft tissue lesion sites) then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one MIBG avid site present at the time of enrollment is required. Soft tissue lesions may be biopsied at any time point prior to enrollment.
  • For MIBG non-avid tumors patient must have at least one FDG avid site and meet the following criteria: i. Biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma from a lesion at any time prior to enrollment of at least one FDG-PET avid site.
  • At least one non-target soft tissue lesion that is not measurable but had a biopsy positive for neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment OR is MIBG avid on planar imaging.
  • Performance Status
  • Patients must have Lansky (≤16 years) or Karnofsky (>16 years) score of ≥50 (Appendix I).
  • Note: Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • Prior Therapy
  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study registration. Patients must not have received the therapies indicated below within the specified time prior to registration on this study as follows:
  • Table 2: Prior Therapies List Type of Therapy Specified Time Period Additional Comments Myelosuppressive Chemotherapy ≤ 14 days This includes cytotoxic agents given on a low dose metronomic regimen as well as retinoids.
  • Biologic Antineoplastic (anti-neoplastic agents)1 ≤ 7 days Monoclonal Antibodies ≤ 7 days or 3 half-lives whichever is longer, but no longer than 30 days (with recovery of any associated toxicities).
  • Cellular Therapy (e.g., modified T cells, NK cells, dendritic cells, etc.) ≤ 21 days and with recovery of all associated toxicities Radiation Small port radiation ≤ 7 days Large field radiation therapy ≤ 12 weeks i.e., total body irradiation, craniospinal, whole abdominal, total lung, > 50% marrow space Other Substantial Bone Marrow Radiation ≤ 6 weeks 131I-MIBG therapy ≤ 6 weeks Hematopoietic Stem Cell Transplant Autologous Stem Cell Infusion Following Myeloablative Therapy ≤ 6 weeks Patients who have received an autologous stem cell infusion to support non-myeloablative therapy (such as 131I-MIBG) are eligible at any time as long as they meet the other criteria for eligibility.
  • Any other investigational agents (covered under another IND) ≤ 14 days
  • Anti-cancer agents not known to be myelosuppressive (e.g., not associated with reduced platelet or ANC counts)
  • Concomitant Therapy Restrictions
  • Patients must not have received the concomitant medications indicated below within the specified time prior to study enrollment or planned treatment start date on this study as follows:
  • No other anti-cancer agents or radiotherapy at the time of study registration or while on study.
  • No short-acting hematopoietic growth factors within 7 days of blood draw documenting eligibility and no long-acting hematopoietic growth factors within 14 days of blood draw documenting eligibility.
  • Patients must not have received 0.5 mg/kg/day (prednisone equivalent) doses of systemic steroids for at least 7 days prior to study enrollment.
  • Inhaled steroids are permitted to treat reactive airways
  • < 2mg/kg of hydrocortisone or equivalent is permitted as blood product premedication to avoid allergic reactions.
  • Physiologic hydrocortisone dosing is permitted for patients with known adrenal insufficiency.
  • The use of dexamethasone as an antiemetic is not permitted.
  • Irinotecan is a substrate for CYP3A4 (major) and CYP2B6 (major). Patients who have received drugs that are strong inducers or inhibitors of CYP3A4 within 7 days prior to study enrollment are not eligible. The use of strong inducers or inhibitors of CYP3A4 (Appendix II) and CYP2B6 (e.g., carbamazepine) should be avoided for the duration of protocol therapy. Consult drug information references for further information. In addition, concomitant use of BCRP inhibitors (cyclosporine, eltrombopag, gefitinib), and UGT1A1 inhibitors (diclofenac, ketoconazole, probenecid, silibinin, nilotinib, and atazanavir) should be avoided due to potential increased risk of irinotecan toxicity.
  • Moderate inducers or inhibitors of CYP3A4 (Appendix II) should also be avoided during protocol therapy if reasonable alternatives exist.
  • Organ Function Requirements
  • Hematologic Function:
  • Patients must meet the following hematologic criteria for enrollment regardless of bone marrow disease involvement:
  • ANC ≥750/μL, (no short-acting hematopoietic growth factors ≤ 7 days of blood draw documenting eligibility and no long-acting hematopoietic growth factors ≤ 14 days of blood draw documenting eligibility); and
  • Platelet count ≥ 75,000/μL, transfusion independent (no platelet transfusions ≤ 7 days of blood draw documenting eligibility).
  • Renal Function
  • Patients must have adequate renal function defined as age-adjusted serum creatinine ≤1.5 ULN for age (see below):
  • Table 3: Age-Adjusted Serum Creatinine Age Maximum Serum Creatine (mg/dL) Male Female
  • 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1 1 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4 > 16 years 1.7 1.4
  • Liver Function
  • Total bilirubin ≤ 1.5 x ULN for age; and,
  • SGPT (ALT) ≤ 225 U/L (≤ 5x ULN). Note that for ALT, the upper limit of normal for all sites is defined as 45 U/L.
  • Cardiac Function
  • Shortening fraction of ≥ 27% by ECHO, or
  • Ejection fraction of ≥ 50% by ECHO or gated radionuclide study.
  • Pulmonary Function
  • No evidence of dyspnea at rest, no exercise intolerance.
  • Adequate Central Nervous System Function
  • Patients with a history of CNS disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment
  • Patients with seizure disorders may be enrolled if seizures are well controlled on anti-seizure medications
  • CNS toxicity ≤ Grade 2
  • Reproductive Function
  • All post-menarchal females must have a negative serum or urine beta-HCG ≤ 7 days prior to registration. Male and female subjects of reproductive age and childbearing potential must agree to use two acceptable methods of birth control (i.e., intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) or to abstain from heterosexual intercourse for the duration of their participation in the study.
  • Central Nervous System (CNS)
  • Patients with a history of intraparenchymal or leptomeningeal based CNS disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment.
  • Patients with skull-based tumors with direct intracranial extension are eligible if there are no neurologic signs or symptoms related to the lesion.

Who cannot join

  • Pregnancy, breast feeding, or unwillingness to use effective contraception during the study will not be entered on this study due to risks of fetal and teratogenic adverse events. Females of childbearing potential must have a negative pregnancy test to be eligible for this study.
  • Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
  • Patients with disease of any major organ system that would compromise their ability to withstand therapy.
  • Patients who have undergone a prior allogeneic stem cell or solid organ transplant.
  • Patients who are on hemodialysis.
  • Patients with an active or uncontrolled infection. Patients on prolonged antifungal therapy are still eligible if they are culture negative, afebrile, and meet other organ function criteria.
Show all 17Show fewer
  • Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C. Testing is not required in the absence of clinical findings or suspicions.
  • Patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible. The only exception is for patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration in order to avoid allergic transfusion reactions. The use of conventional doses of inhaled steroids for the treatment of reactive airway disease is permitted, as is the use of physiological doses of steroids for patients with known adrenal insufficiency.
  • Patients on any other immunosuppressive medications (e.g., cyclosporine, tacrolimus) are not eligible.
  • Patients must not have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, or carbamazepine for at least 7 days prior to study enrollment. Patients receiving non-enzyme inducing anticonvulsants such as gabapentin, valproic acid, or levetiracetam will be eligible.
  • Patients who have received drugs that are strong inducers or inhibitors of CYP3A4 within 7 days prior to study enrollment are not eligible.
  • Patients must not have been diagnosed with myelodysplastic syndrome or with any malignancy other than neuroblastoma.
  • Patients with symptoms of congestive heart failure are not eligible.
  • Patients must not have > Grade 2 diarrhea.
  • Patients with a history of progressive disease while receiving therapy per ANBL1221 (irinotecan/temozolomide/dinutuximab/GMCSF).
  • Patients with a history of Grade 4 allergic reactions to anti-GD2 antibodies or reactions that required permanent discontinuation of the anti-GD2 therapy are not eligible.
  • Patients with elevated catecholamines (i.e., > 2 x ULN) only and no evidence of disease are NOT eligible for this study.

Trial locations and contacts

5 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Sara Federico, MD contact

888-226-4343

referralinfo@stjude.org

5 sites in 1 country

United States5 sites, 5 recruiting

  • Motts Childrens Hospital

    Ann Arbor, Michigan, 48109

    Rajen Mody, MBBS

    Rajen MOdy, MBBS

    Not yet recruiting

  • Children's Hospital of Colorado

    Aurora, Colorado, 80902

    Not yet recruiting

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105

    Sara Federico, MD, 888-226-4343, referralinfo@stjude.org

    Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104

    John Maris, MD

    John Maris, MD

    Recruiting

  • University of California San Francisco

    San Francisco, California, 94158

    Kieuhoa Vo, MD

    Kieuhoa Vo, MD

    Not yet recruiting

Other trials in United States

About this study

Official title: A Phase II Study With a Safety Run-In of the Addition of N-803, a Novel IL-15 Super-Agonist, to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

The study participant is being asked to take part in this research study because the participant has been diagnosed with neuroblastoma that did not fully respond to previous treatment (refractory), or it has returned after treatment (relapsed).

Primary Aims

Read more
  • To evaluate if the administration of N-803 in combination with irinotecan, temozolomide, hu14-18K322A, and GM-CSF in patients with relapsed/refractory neuroblastoma is feasible and tolerable
  • To determine if the response rate of N-803 with irinotecan, temozolomide, hu14.18K322A and GM-CSF in patients with relapsed/refractory neuroblastoma is superior to the combination of irinotecan, temozolomide, hu14.18K322A, and GM-CSF

Secondary Aims

  • To describe the toxicity profile of N-803 administered with irinotecan, temozolomide, hu14.18K322A and GM-CSF
  • To evaluate and compare the progression free survival (PFS) and overall survival (OS) of and between patients receiving irinotecan, temozolomide, hu14.18K322A and GM-CSF with and without N-803
Read the detailed description

This is a randomized phase 2 study with a safety assessment run-in conducted in children with relapsed or refractory neuroblastoma to evaluate the feasibility, tolerability, and response to chemoimmunotherapy backbone (irinotecan, temozolomide, hu14.18K322A and GM-CSF) with or without N-803. The first 6 patients included in the safety assessment run-in phase will receive irinotecan, temozolomide, hu14.18K322A, GM-CSF and N-803. If fewer than 2 patients in the first cohort of 6 patients experience a DLT in Cycle 1, then the trial will proceed Phase 2. If 2 or more of the first 6 patients experience a DLT in Cycle 1 then the N-803 will be dose reduced, and 6 more patients will be enrolled in the safety assessment run-in.

Once the safety assessment run-in phase is completed, patients will be enrolled onto the phase 2 study. In the phase 2 study, patients will be randomized to receive either chemoimmunotherapy alone (Arm A) or chemoimmunotherapy plus N-803 (Arm B). Patients treated on Arm A who experience disease progression may cross over at any time point after completing Cycle 2 and receive therapy administered on Arm B. Pharmacokinetic and correlative biology studies will be performed throughout the study.

Being tested
Temozolomide, Irinotecan, hu14.18K322A, N803, Sargramostim
Keywords
relapse, refractory
Medical subject headings
Recurrence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TemozolomideDrug

    IV, Days 1-5

  • IrinotecanDrug

    IV, Days 1-5

  • hu14.18K322ADrug

    IV over 4 hours daily times 4 doses, Days 2-5.

  • N803Drug

    Subcutaneous (SC), Day 6.

  • SargramostimDrug

    Also called GMCSF

    Subcutaneous injection (preferred) or IV, Days 7-13.

Study groups in NCT07085338
Study groupRoleWhat they receive
ChemoimmunotherapyExperimentalPatients will be randomized to receive chemoimmunotherapy alone.
Receives: Drug: Temozolomide; Drug: Irinotecan; Drug: hu14.18K322A; Drug: Sargramostim
Chemoimmunotherapy + N-803ExperimentalPatients will be randomized to receive chemoimmunotherapy plus N-803.
Receives: Drug: Temozolomide; Drug: Irinotecan; Drug: hu14.18K322A; Drug: N803; Drug: Sargramostim
Safety Run-In Treatment Schedule - Chemoimmunotherapy + N-803ExperimentalThe first 6 patients included in the safety assessment run-in phase will receive cycles of irinotecan, temozolomide, hu14.18K322A, GM-CSF and N-803. If fewer than 2 patients in the first cohort of 6 patients experience a DLT in Cycle 1, then the trial will proceed to Phase 2. If 2 or more of the first 6 patients experience a DLT in Cycle 1 then the N-803 will be dose reduced to 15 mcg/kg and 6 more patients will be enrolled in the safety assessment run-in. Once the safety assessment run-in phase is completed, patients will be enrolled onto the phase 2 study.
Receives: Drug: Temozolomide; Drug: Irinotecan; Drug: hu14.18K322A; Drug: N803; Drug: Sargramostim

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To evaluate if the administration of N-803 in combination with irinotecan, temozolomide, hu14-18K322A, and GM-CSF in patients with relapsed/refractory neuroblastoma is feasible

    Feasibility Measures: Patients evaluable for toxicity in the safety run-in must receive one dose of N-803. The proportion of evaluable patients who successfully complete the protocol-defined treatment regimen in the Safety Run-in phase will be calculated. The reasons for treatment discontinuation or deviations from the protocol will be summarized.

    Measured: Complete Cycle 1 treatment (each cycle is 21 days)

  2. To determine if the response rate of N-803 with irinotecan, temozolomide, hu14.18K322A and GM-CSF in patients with relapsed/refractory neuroblastoma is superior to the combination of irinotecan, temozolomide, hu14.18K322A, and GM-CSF

    Tolerability Assessments: Tolerability of the protocol-defined treatment in the Safety Run-in phase will be determined by assessing adverse events and their severity. Adverse events will be categorized based on standard CTCAE v5.0 criteria. Dose modifications or interruptions resulting from treatment-related adverse events will be analyzed.

    Measured: Complete Cycle 1 treatment (each cycle is 21 days)

  3. To determine if the response rate of N-803 with irinotecan, temozolomide, hu14.18K322A and GM-CSF in patients with relapsed/refractory neuroblastoma is superior to the combination of irinotecan, temozolomide, hu14.18K322A, and GM-CSF

    Tumor response will be assessed using standard NANT criteria. The primary endpoint for response analysis will be Best Overall Response (BOR), defined as the best response observed prior to progression, cross over or start of another therapy. Point estimates for the response rate (proportion of patients who have BOR of PR or better) will be calculated, together with exact 95% confidence intervals.

    Measured: Up to 10 cycles of irinotecan/temozolomide/hu14.18K322A/GM-CSF with or without N-803 in the Phase 2 (each cycle is 21 days)

Secondary outcomes (3)

  1. To describe the toxicity profile of N-803 administered with irinotecan, temozolomide, hu14.18K322A and GM-CSF

    Toxicities will be graded using CTCAE v5.0. The toxicity profile will be defined as a comprehensive assessment of adverse events, categorized by standard toxicity criteria. The frequency, type, and severity and attribution of adverse events will be calculated and summary statistics for the toxicity profile will be provided.

    Measured: Up to 10 cycles of irinotecan/temozolomide/hu14.18K322A/GM-CSF with or without N-803 in the Phase 2 (each cycle is 21 days)

  2. To evaluate and compare the progression free survival (PFS) of and between patients receiving irinotecan, temozolomide, hu14.18K322A and GM-CSF with and without N-803

    Progression-Free Survival (PFS) is defined as the time from the start of treatment to disease progression or death from any cause. Time from the day of receiving irinotecan, temozolomide, hu14.18K322A and GM-CSF with and without N-803 to the day of development of any progression or death will be assessed by the Kaplan-Meier method separately. The PFS rate will be estimated along with the corresponding 95% CI. A log-rank test will be used to compare between the two groups with and without N-803.

    Measured: Time from enrollment (phase I) or randomization (phase II) to disease progression, death, or last follow-up, whichever is earlier, assessed up to 36 months

  3. To evaluate and compare overall survival (OS) of and between patients receiving irinotecan, temozolomide, hu14.18K322A and GM-CSF with and without N-803

    Overall Survival (OS) is defined as the time from the start of treatment to death from any cause. Time from the day of receiving irinotecan, temozolomide, hu14.18K322A and GM-CSF with and without N-803 to the day of development of any progression or death will be assessed by the Kaplan-Meier method separately. The OS rate will be estimated along with the corresponding 95% CI. A log-rank test will be used to compare between the two groups with and without N-803.

    Measured: Time from date of enrollment (phase I) or randomization (phase II) until the date of death from any cause, or last follow-up, whichever is earlier, assessed up to 36 months.]

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jul 2025
  2. Study start10 Nov 2025
  3. Primary completion1 Feb 2028 (estimated)
  4. Study completion1 Feb 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
54 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07085338
Sponsor's protocol ID
HuNB803
Other IDs
NCI-2025-02707
Status last verified
Aug 2026
First submitted
9 Apr 2025
Last updated
7 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Temozolomide, Irinotecan and hu14.18K322A in people with Neuroblastoma Recurrent, run by St. Jude Children's Research Hospital at 5 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 78 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sara Federico, MD (888-226-4343, referralinfo@stjude.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To evaluate if the administration of N-803 in combination with irinotecan, temozolomide, hu14-18K322A, and GM-CSF in patients with relapsed/refractory neuroblastoma is feasible (time frame: Complete Cycle 1 treatment (each cycle is 21 days)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07085338.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in